通过PARP抑制剂对CDK12缺乏前列腺癌进行合成致命向
Jonathan Chou1,2, Troy M Robinson1,3, Emily A Egusa1,3
1UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California.
概括
具有CDK12突变的前列腺癌细胞对PARP抑制剂 (PARPi) 更敏感. 鲁卡帕里布在临床前模型和临床试验中显示出有效性,这表明PARPi单一治疗特定的CDK12突变前列腺癌.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 遗传学 遗传学 是一个
背景情况:
- 循环素依赖激酶 (CDK),CDK12,在各种癌症中经常发生变化.
- 一种特定的前列腺癌亚型表现出CDK12的功能丧失突变,与侵袭性疾病相关.
- 了解CDK12的作用对于开发向疗法至关重要.
研究的目的:
- 研究CDK12突变对前列腺癌对PARP抑制剂 (PARPi) 敏感性的影响.
- 评估针对CDK12突变前列腺癌的潜在治疗策略.
- 评估rucaparib在临床前模型和临床环境中的疗效.
主要方法:
- 使用CRISPR/Cas9来禁用CDK12,生成了异构性前列腺癌模型.
- 对FDA批准的药物进行了化学图书馆的检查.
- 抑制环林K和CDK13以评估对PARPi敏感性的影响.
- 利用了具有CDK12截断和酶域突变的细胞系.
- 携带CDK12突变前列腺瘤的小鼠接受了rucaparib的治疗.
- 在TRITON2试验中用rucaparib治疗的CDK12突变患者的PSA反应评估.
主要成果:
- 缺乏CDK12的癌细胞对PARPi的敏感性增加.
- 抑制环林K,但不是CDK13,赋予了PARPi灵敏度和受损的同源重组.
- CDK12截断突变体对PARPi敏感,而激酶域突变体表现出中间敏感性.
- 在患有CDK12突变前列腺瘤的小鼠中,Rucaparib治疗抑制了瘤生长.
- 55%的双基CDK12突变患者在接受rucaparib治疗时经历了PSA降低.
结论:
- 前列腺癌中PARPi的敏感性取决于CDK12突变的特定类型和密度.
- 单独治疗PARPi可能是前列腺癌患者的可行治疗选择,其中包括双基无活化CDK12变异.
相关概念视频
02:57Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
02:34Inhibition of Cdk Activity
4.7K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
02:15M-Cdk Drives Transition Into Mitosis
5.5K
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.5K
01:23Negative Regulator Molecules
35.2K
Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
35.2K
02:50Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
02:37DNA Damage can Stall the Cell Cycle
9.1K
In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
9.1K